Michael J. Morris, MD | Authors

SARATOGA HOSPITAL PHARMACY

211 CHURCH ST

Articles

CHAARTED: ADT Plus Docetaxel in Prostate Cancer

June 30, 2014

Dr. Morris discusses results and implications of the CHAARTED trial, which studied the survival impact of androgen deprivation therapy (ADT) plus docetaxel vs ADT alone for hormone-sensitive newly metastatic prostate cancer.